Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Posted on by sHq_LoGiNz

TOKYO–(BUSINESS WIRE)–Enhertu Demonstrated a Median 14.3 Month Progression-Free Survival as First-Line Therapy in Patients with HER2 Mutant Advanced NSCLC in DESTINY-Lung04

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.